Table 4 Multivariate model for overall survival for chemotherapy cohort (n = 4102)
From: Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients
Characteristic | Stage II (n = 1631) | Stage III (n = 2441) | |
|---|---|---|---|
Multivariate | Multivariate | ||
HR (95% CI) | HR (95% CI) | ||
Sided | Left | 1 | 1 |
Right | 0.86 (0.68–1.09) | 1.29 (1.11–1.50) | |
Age | ≤60 | 1 | 1 |
61–70 | 1.90 (1.20–2.99) | 1.21 (0.94–1.54) | |
71–80 | 2.97 (1.92–4.58) | 1.81 (1.43–2.30) | |
>80 | 5.92 (3.82–9.19) | 2.00 (1.54–2.60) | |
Grade | Well/mod differentiated | 1 | 1 |
Poorly Differentiated | 1.43 (1.08–1.90) | 1.49 (1.26–1.75) | |
TNM stage | IIIa | 1 | 1 |
IIIb | 2.20 (1.71–2.82)a | 1.79 (1.33–2.43) | |
IIIc | - | 3.86 (2.84–5.24) | |
Sex | Male | 1 | 1 |
Female | 0.85 (0.68–1.07) | 0.94 (0.82–1.10) | |
CCI | 0 | 1 | 1 |
1–2 | 1.42 (1.09–1.52) | 1.15 (0.96–1.38) | |
3–4 | 1.60 (1.12–2.28) | 1.20 (0.94–1.53) | |
5 | 2.31 (1.45–3.69) | 1.83 (1.36–2.46) | |
Year Diagnosed | 2006–2009 | 1 | 1 |
2010–2013 | 0.99 (0.79–1.26) | 1.00 (0.86–1.17) | |
Adjuvant Chemotherapy | Nil | 1 | 1 |
Fluorouracil monotherapy | 0.79 (0.51–1.10)b | 0.48 (0.40–0.57) | |
Oxaliplatin doublet | - | 0.38 (0.27–0.42) | |